Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 11 of 30
Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling
NCT04341363
Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling
NCT04338295
Autism Biomarker Consortium for Clinical Trials (ABC-CT): Follow-up Study
NCT04841525
Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling
NCT04342091
Targeting the Gut-brain Axis to Facilitate Weight Loss in High Fat Diet Consumers
NCT04614233
Parent Training for Youth With Chronic Symptoms
NCT04277715
Respiratory Supports and COVID-19 Mortality
NCT04832061
Quit Nicotine: E-Cig Cessation Intervention
NCT04898075
CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)
NCT04684641
Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923
NCT04805983
Stimulation Therapy for Inducing Mothers
NCT04756089
Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention
NCT04760652
A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia
NCT04457310
A Digital Intervention to Prevent Initiation of Opioid Misuse in Adolescents in School-based Health Centers
NCT04109599
Inhibition of Sterile Inflammation by Digoxin
NCT03559868
Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial
NCT04561765
Behavioral Weight Loss Treatment for Individuals With Food Addiction
NCT04311450
Pathway to Detection & Differentiation of Delirium & Dementia in the Emergency Department
NCT04846322
Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure
NCT05093621
Mindful Kala: Virtual Bharatanatyam Wellness Program for Students
NCT04745364
Mindfulness-Based ADHD Treatment for Children: a Feasibility Study
NCT04737512
Gocheck Kids vs. Welch Allyn Spot Vision Screener
NCT04321538
Investigating Stress-related Mechanisms in the Laboratory and Real World in Individuals With Cannabis Use Disorder
NCT04116619
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
NCT04779697
Pragmatic Trial of Messaging to Providers About Treatment of Heart Failure
NCT04514458
Feasibility, Acceptability, and Barriers to Implementation of a Geriatrics Bundle in the ICU
NCT04652453
COVID-19 Responsive Intervention: Systems Improvement Simulations (CRI:SIS)
NCT04614844
Effects of Hepatic Ultrasound on Metabolic Homeostasis
NCT04622683
Continuous Non-invasive Hemodynamic Monitoring in Early-onset Severe Preeclampsia: a Comparison of Echocardiography, Bioreactance, and Finger Cuff Measurements
NCT05299229
Parental Guidance for Failure to Launch.
NCT04704583
IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)
NCT04575610
Pharmacokinetics and Hepatic Safety of EGCG
NCT04177693
Smartband Mindfulness Study
NCT03995225
Perinatal Attentional Retraining Intervention for Smoking for Minority Women
NCT04114877
The Effect of Lactation on Insulin Sensitivity and Lipolysis in Women
NCT04146909
Measuring the Impact of Real Time fMRI Neurofeedback in Borderline Personality Disorder
NCT04306341
The Interaction of Flavor With Nicotine Form in Adult Smokers
NCT04262817
Combining Varenicline and Guanfacine for Smoking Cessation
NCT04198116
Efficacy of Laparoscopic-assisted Transversus Abdominus Plane (TAP) Block Compared to Ultrasound-guided TAP Block in Minimally Invasive Gynecologic Surgeries: A Prospective, Randomized Control Trial.
NCT04345341
Song-making In a Group (SING) R61
NCT05537428
Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial
NCT04472611
Tofacitinib for Treatment of Moderate COVID-19
NCT04415151
vDPP Facilitated With Community Care Coordination
NCT04195477
Cognitive-Behavioral Therapy for Weight-related Bullying (Online Treatment)
NCT04587752
Assessing Mental Health Providers' Clinical Knowledge and Skills Via an Online Training on LGBTQ-affirmative Cognitive-behavioral Therapy
NCT04559698
Being Present With Art: The Impact of Mindful Engagement With Art on Awareness and Connection
NCT04722367
FAAH Availability in Psychiatric Disorders: A PET Study
NCT04404712
Evaluating Efficacy of Digital Health Technology in the Treatment of Congestive Heart Failure
NCT04394754
An Intervention to Correct Dualistic Reasoning About the Effectiveness of Psychotherapy for Biologically Caused Mental Disorders
NCT05800119
Variation in Opioid Prescribing and Use for Acute Pain in Diverse Populations
NCT04509115
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yale University pipeline card: 1,492 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.